Safety and Efficacy of AL-53817 Nasal Spray Solution in Ragweed Sensitive Subjects in an Environmental Exposure Chamber (EEC)
Phase of Trial: Phase I
Latest Information Update: 17 May 2013
At a glance
- Drugs AL 53817 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Oct 2011 New trial record
- 18 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.